A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma
Authors
Keywords
-
Journal
JOURNAL OF NEURO-ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-11-27
DOI
10.1007/s11060-019-03337-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial
- (2019) Patrick Y. Wen et al. JOURNAL OF CLINICAL ONCOLOGY
- Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation
- (2019) Sabrina Baltschukat et al. CLINICAL CANCER RESEARCH
- Brain Tumors
- (2018) J. Ricardo McFaline-Figueroa et al. AMERICAN JOURNAL OF MEDICINE
- Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor–Dysregulated Non–Small-Cell Lung Cancer
- (2018) Yi-Long Wu et al. JOURNAL OF CLINICAL ONCOLOGY
- LBA52Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14 mutated advanced non-small cell lung cancer (NSCLC)
- (2018) J Wolf et al. ANNALS OF ONCOLOGY
- Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM xenografts and prolongs survival in nude rats
- (2016) I. A. Netland et al. JOURNAL OF NEURO-ONCOLOGY
- Recurrent MET fusion genes represent a drug target in pediatric glioblastoma
- (2016) NATURE MEDICINE
- Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer
- (2015) Johan F. Vansteenkiste et al. Journal of Thoracic Oncology
- Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression
- (2015) H Kotani et al. ONCOGENE
- Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated withALK‘borderline’-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies
- (2014) M. I. Ilie et al. ANNALS OF ONCOLOGY
- Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors
- (2014) Yuichi Ando et al. CANCER SCIENCE
- Disruption of Follicular Dendritic Cells-Follicular Lymphoma Cross-talk by the Pan-PI3K Inhibitor BKM120 (Buparlisib)
- (2014) A. Matas-Cespedes et al. CLINICAL CANCER RESEARCH
- RNA-seq of 272 gliomas revealed a novel, recurrentPTPRZ1-METfusion transcript in secondary glioblastomas
- (2014) Zhao-Shi Bao et al. GENOME RESEARCH
- Parallel FISH and Immunohistochemical Studies of ALK Status in 3244 Non–Small-Cell Lung Cancers Reveal Major Discordances
- (2014) Florian Cabillic et al. Journal of Thoracic Oncology
- The Somatic Genomic Landscape of Glioblastoma
- (2013) Cameron W. Brennan et al. CELL
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
- (2013) Garrett M Frampton et al. NATURE BIOTECHNOLOGY
- A Novel Kinase Inhibitor, INCB28060, Blocks c-MET-Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3
- (2011) X. Liu et al. CLINICAL CANCER RESEARCH
- Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
- (2011) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
- (2010) Patrick Y. Wen et al. JOURNAL OF CLINICAL ONCOLOGY
- A study of HER2 gene amplification and protein expression in gastric cancer
- (2010) B. Yan et al. JOURNAL OF CLINICAL PATHOLOGY
- The clinicopathologic values of the molecules associated with the main pathogenesis of the glioblastoma
- (2010) Bomi Kim et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Downregulation of uPAR and Cathepsin B Induces Apoptosis via Regulation of Bcl-2 and Bax and Inhibition of the PI3K/Akt Pathway in Gliomas
- (2010) Ramarao Malla et al. PLoS One
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More